Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Leonard SN.

PLoS One. 2012;7(7):e42103. doi: 10.1371/journal.pone.0042103. Epub 2012 Jul 24.

2.

Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.

Leonard SN, Supple ME, Gandhi RG, Patel MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2678-83. doi: 10.1128/AAC.02127-12. Epub 2013 Apr 1.

3.

Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus.

Leonard SN, Rolek KM.

J Antimicrob Chemother. 2013 Mar;68(3):644-7. doi: 10.1093/jac/dks453. Epub 2012 Nov 14.

PMID:
23152482
5.

In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2012 Jan;56(1):202-7. doi: 10.1128/AAC.05473-11. Epub 2011 Oct 17.

6.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

7.

Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Dilworth TJ, Leonard SN, Vilay AM, Mercier RC.

Clin Ther. 2014 Oct 1;36(10):1334-44. doi: 10.1016/j.clinthera.2014.06.027. Epub 2014 Jul 25.

PMID:
25066667
8.

Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.

Hu J, Ma XX, Tian Y, Pang L, Cui LZ, Shang H.

PLoS One. 2013 Sep 12;8(9):e73300. doi: 10.1371/journal.pone.0073300. eCollection 2013.

9.
10.

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Vidaillac C, Leonard SN, Rybak MJ.

Antimicrob Agents Chemother. 2009 Nov;53(11):4712-7. doi: 10.1128/AAC.00636-09. Epub 2009 Sep 8.

12.

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Smith JR, Yim J, Raut A, Rybak MJ.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. doi: 10.1128/AAC.03006-15. Print 2016 Apr.

14.
15.

Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).

Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.

Int J Antimicrob Agents. 2011 Jun;37(6):558-61. doi: 10.1016/j.ijantimicag.2011.02.007. Epub 2011 Apr 14.

PMID:
21497067
17.

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12.

18.

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.

Vidaillac C, Leonard SN, Rybak MJ.

Int J Antimicrob Agents. 2010 Jun;35(6):527-30. doi: 10.1016/j.ijantimicag.2010.02.006. Epub 2010 Mar 26.

PMID:
20346632
20.

Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.

Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.

J Antimicrob Chemother. 2011 Jul;66(7):1594-9. doi: 10.1093/jac/dkr169. Epub 2011 Apr 26.

PMID:
21525024

Supplemental Content

Support Center